The survey found that, for the United States specifically, in the informed public segment, there was a 20% drop in the general trust in healthcare, giving the United States market the second biggest drop following Colombia. Globally, trust declined in 16 of 28 markets studied, noting an average 4% decline in trust in healthcare globally.
Edelman has released the findings from the “Edelman’s Trust Barometer in Healthcare” survey. The online survey polled individuals from 28 global healthcare markets and had over 33,000 respondents. The survey was conducted between October 28, 2017 and November 20, 2017.
The report found that of the 28 markets that were polled, trust declined in 17 markets from 2017 to 2018. The survey classified respondents into 2 categories: the general online population, and the informed public. Participants earn the “informed public” distinction, a designation which represents 15% of the global population, by meeting 4 criteria: aged 25 to 64, college educated, in the top 25% of household income per age group in each market, and reported significant media consumption and engagement in business news.
The survey found that, for the United States specifically, in the informed public segment, there was a 20% drop in the general trust in healthcare, giving the United States market the second biggest drop following Colombia. Globally, trust declined in 16 of 28 markets studied, noting an average 4% decline in trust in healthcare globally.
In addition, global trust in the pharmaceutical industry remained unchanged, but several markets saw double-digit shifts. The survey found that, in 12 out of 28 markets polled, the pharmaceutical subsector is distrusted. Specifically, in the United States, the report noted that the trust in the pharmaceutical market dropped 13% between 2017 and 2018, largely due to the public’s placing blame on pharmaceutical companies for the high cost of drugs, as well as the aggressive marketing of opioids.
Conversely, the global trust in health insurance and hospitals saw an increase across all age groups worldwide. In hospitals and clinics specifically, trust has continued to increase, with 24 of 28 markets noting that their trust in these institutions rose. Globally, health insurance gained 1 percentage point on average, moving the market toward a perception of trustworthiness. However, due to uncertainty over the fate of the Affordable Care Act and ongoing debates over drug pricing, the United States posted a 9% decrease in trust in health insurers.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.